Arcus Biosciences, Inc.
RCUS
$9.16
$0.030.33%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 141.00M | 258.00M | 263.00M | 247.00M | 237.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 141.00M | 258.00M | 263.00M | 247.00M | 237.00M |
| Cost of Revenue | 356.00M | 343.00M | 335.00M | 294.00M | 293.00M |
| Gross Profit | -215.00M | -85.00M | -72.00M | -47.00M | -56.00M |
| SG&A Expenses | 116.00M | 120.00M | 121.00M | 121.00M | 119.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 577.00M | 568.00M | 561.00M | 520.00M | 487.00M |
| Operating Income | -436.00M | -310.00M | -298.00M | -273.00M | -250.00M |
| Income Before Tax | -390.00M | -282.00M | -269.00M | -246.00M | -227.00M |
| Income Tax Expenses | 1.00M | 1.00M | 1.00M | 3.00M | 4.00M |
| Earnings from Continuing Operations | -391.00 | -283.00 | -270.00 | -249.00 | -231.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -391.00M | -283.00M | -270.00M | -249.00M | -231.00M |
| EBIT | -436.00M | -310.00M | -298.00M | -273.00M | -250.00M |
| EBITDA | -426.00M | -300.00M | -288.00M | -264.00M | -241.00M |
| EPS Basic | -4.19 | -3.10 | -3.15 | -3.10 | -3.10 |
| Normalized Basic EPS | -2.61 | -1.79 | -1.82 | -1.77 | -1.76 |
| EPS Diluted | -4.19 | -3.10 | -3.15 | -3.10 | -3.10 |
| Normalized Diluted EPS | -2.61 | -1.79 | -1.82 | -1.77 | -1.76 |
| Average Basic Shares Outstanding | 372.60M | 360.40M | 343.70M | 326.90M | 309.00M |
| Average Diluted Shares Outstanding | 372.60M | 360.40M | 343.70M | 326.90M | 309.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |